on NOVACYT (EPA:ALNOV)
Novacyt: HSE action against Lab 21 ends
Novacyt SA, a molecular diagnostics company, has announced the conclusion of proceedings brought by the Health and Safety Executive (HSE) against its subsidiary Lab 21 Healthcare Ltd. The hearing, held on 11 September 2025, ordered Lab 21 to pay a fine of £52,000 following a guilty plea relating to health and safety breaches between June 2018 and April 2019 at the Axminster site. This amount will be paid from available funds and will not materially affect the group's financial position. The case is now closed, with no further legal consequences expected.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NOVACYT news